# Cannabinoid Effects of Metamizol/Dipyrone: A Possible Second Life in Pediatric Anesthesia for a Vintage Drug. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/metamizol-pediatric-anesthesia-cannabinoid-effects/ > **Published:** 2026-03-24T20:06:02-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:40:01-04:00 > **Clinical Summary:** Explore metamizol pediatric anesthesia and its cannabinoid effects, revealing new insights for safer pediatric analgesia protocols. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic PainPediatricAnesthesiaEndocannabinoidAnalgesia Journal Biomedicines Study Type Clinical Study Population Human participants Why This Matters This study explores metamizol’s cannabinoid-like properties, which could explain its analgesic mechanisms and inform safer pediatric anesthesia protocols. Understanding these pathways may help clinicians optimize multimodal analgesia while potentially reducing opioid requirements in vulnerable populations. Clinical Summary This clinical study investigates metamizol (dipyrone), a non-opioid analgesic banned in several countries but widely used elsewhere, examining its interactions with cannabinoid pathways in human participants undergoing pediatric anesthesia procedures. The research suggests metamizol may exert analgesic effects through [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) modulation, particularly CB1 and [CB2 receptor](https://cedclinic.com/s-caryophyllene-a-terpine-found-in-cannabis-demonstrates-therapeutic-potential-in-a-mouse-model-of-ms/) interactions, which could explain its efficacy profile distinct from traditional NSAIDs. The study provides mechanistic insights into why this vintage analgesic demonstrates unique therapeutic properties in [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/). Notable limitations include the drug’s controversial safety profile and variable regulatory status globally. Dr. Caplan’s Take “While mechanistically interesting, this doesn’t change my current practice since metamizol remains unavailable in the US due to agranulocytosis concerns. The cannabinoid pathway connection is intriguing but needs more safety data before clinical application.” Clinical Perspective 🧠 Clinicians should view this as preliminary mechanistic research rather than actionable clinical guidance, especially given metamizol’s restricted availability and safety concerns. For patients in regions where metamizol is available, this research may inform future multimodal analgesia strategies, but established safety protocols remain paramount in pediatric populations. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabinoid%20Effects%20of%20Metamizol/Dipyrone%3A%20A%20Possible%20Second%20Life%20in%20Pediatric%20A...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41751257/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41751257/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabinoid%20Effects%20of%20Metamizol/Dipyrone%3A%20A%20Possible%20Second%20Life%20in%20Pediatric%20A...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41751257/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41751257/](https://pubmed.ncbi.nlm.nih.gov/41751257/) Table of Contents - [FAQ](#FAQ)[What is metamizol/dipyrone and how does it relate to cannabinoid effects?](#What_is_metamizoldipyrone_and_how_does_it_relate_to_cannabinoid_effects) - [Why is metamizol being reconsidered for pediatric anesthesia?](#Why_is_metamizol_being_reconsidered_for_pediatric_anesthesia) - [Is metamizol safe for use in children given its controversial history?](#Is_metamizol_safe_for_use_in_children_given_its_controversial_history) - [How do the cannabinoid effects of metamizol differ from medical cannabis?](#How_do_the_cannabinoid_effects_of_metamizol_differ_from_medical_cannabis) - [What clinical evidence supports using metamizol in pediatric anesthesia?](#What_clinical_evidence_supports_using_metamizol_in_pediatric_anesthesia) - [Related](#Related) ## FAQ #### What is metamizol/dipyrone and how does it relate to cannabinoid effects? Metamizol (dipyrone) is a non-opioid analgesic that has been found to interact with the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/). This study explores how this “vintage” pain medication may produce some of its analgesic effects through cannabinoid pathways, potentially offering new insights into its mechanism of action. #### Why is metamizol being reconsidered for pediatric anesthesia? The discovery of metamizol’s cannabinoid-mediated effects provides a new rationale for its use in pediatric [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/). Its endocannabinoid system interaction may offer effective analgesia with potentially fewer side effects compared to traditional opioid-based approaches in children. #### Is metamizol safe for use in children given its controversial history? While metamizol was withdrawn from many markets due to rare but serious blood disorders, it remains widely used in several countries with careful monitoring. The cannabinoid mechanism findings may help optimize dosing and patient selection to maximize benefits while minimizing risks in pediatric populations. #### How do the cannabinoid effects of metamizol differ from medical cannabis? Unlike direct cannabis administration, metamizol appears to work through the body’s endogenous cannabinoid system without producing psychoactive effects. This indirect cannabinoid pathway activation may provide [therapeutic benefits](https://cedclinic.com/therapeutic-benefits-of-thc/) while maintaining the safety profile needed for pediatric anesthesia applications. #### What clinical evidence supports using metamizol in pediatric anesthesia? This research is currently classified as “monitored relevance,” indicating it represents an early-stage finding requiring additional clinical evidence before implementation. More studies are needed to establish definitive safety and efficacy protocols for pediatric anesthetic applications based on these cannabinoid mechanisms. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Cannabinoid Effects of Metamizol/Dipyrone: A Possible Second Life in Pediatric Anesthesia for a Vintage Drug.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41751257/”, “about”: “biomedicines clinical study cannabinoid effects metamizol”, “isPartOf”: “Biomedicines”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Letter by Wu et al Regarding Article on Cannabinoid Receptor 2](https://cedclinic.com/cannabinoid-receptor-2-phosphorylation-diabetic-heart-injury/) A detailed discussion on cannabinoid receptor 2 phosphorylation and its implications in diabetic heart injuries. [Read the Letter](https://cedclinic.com/cannabinoid-receptor-2-phosphorylation-diabetic-heart-injury/) [Cannabinoid Therapies in Less-Common Disorders](https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/) Explore clinical evidence and formulation strategies for cannabinoid therapies beyond common indications. [Explore Therapies](https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/) [Opioids and Cannabis: An Uncertain Combination?](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) Review the complexities and clinical considerations of combining opioids with [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). [Learn More](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).